ACTG 260: A randomized, phase I-II, dose-ranging trial of the anti- human immunodeficiency virus activity of delavirdine monotherapy

Michael F. Para, Patricia Meehan, Jeanne Holden-Wiltse, Margaret Fischl, Gene Morse, Robert Shafer, Lisa M. Demeter, Kenneth Wood, Tom Nevin, Nzeera Virani-Ketter, William W. Freimuth

Research output: Contribution to journalArticlepeer-review

29 Scopus citations

Fingerprint Dive into the research topics of 'ACTG 260: A randomized, phase I-II, dose-ranging trial of the anti- human immunodeficiency virus activity of delavirdine monotherapy'. Together they form a unique fingerprint.

Medicine & Life Sciences